Provided are methods of enhancing immunogenicity of cancers. In certain aspects, the methods include administering an effective amount of a sialic acid modulator to an individual identified as having a cancer comprising dysregulated Myc. According to some aspects, the methods include administering an effective amount of a disialyl-T modulator to an individual identified as having a cancer comprising cell surface expression of disialyl-T. In certain aspects, the methods include administering an effective amount of an agent to an individual identified as having a cancer comprising cell surface expression of a glycoprotein comprising an O-glycosylated mucin-like domain, where the agent modulates the glycoprotein. Also provided are methods of assessing whether a cancer of an individual comprises dysregulated Myc.

An analytical process for detecting antibody in human blood serum, which antibody is directed against blood group antigen, wherein the serum contains an additional antibody directed against a surface antigen, by contacting the serum to be analysed with blood cell membranes, which naturally bear surface blood group antigens, followed by detection of agglutination which indicated the presence of antibody directed against at least one surface antigen of the blood cell membranes. The agglutination reaction caused by the additional antibody is prevented, allowing the detection of anti-blood group antibody.

IgG epitope and applications thereof as a target are provided. The IgG epitope is the C.sub.H1 domain of non-B cell-derived IgG, and there is N-glycosylated sialic acid modification at the Asn162 site of the domain. The realization of its antigen functions must depend on the sialylation of the site. The present invention further discloses the applications of the IgG epitope as a drug target in preparing drugs for diagnosis and/or treatment of epithelial tumors. In addition, our studies showed that this antigen depends on the sialylation of Asn162 site as a drug target, and the sialylation of this site must depend on sialyltransferase ST3GAL4, indicating that the enzyme can be used as a drug target for preparing tumor therapeutic drugs. Further, integrin 4 is co-expressed and co-localized with IgG containing the epitope. IgG can be used as a marker for preparing drugs for the auxiliary detection of epithelial tumors.

The present disclosure relates to anti-CD38 antibodies and their use as therapeutics and diagnostics. The present disclosure further relates to methods of treating autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis. The present disclosure further relates to diagnostic assay methods for identifying patients having autoimmune diseases for treatment.

An analytical process for detecting antibody in human blood serum, which antibody is directed against blood group antigen, wherein the serum contains an additional antibody directed against a surface antigen, by contacting the serum to be analysed with blood cell membranes, which naturally bear surface blood group antigens, followed by detection of agglutination which indicated the presence of antibody directed against at least one surface antigen of the blood cell membranes. The agglutination reaction caused by the additional antibody is prevented, allowing the detection of anti-blood group antibody.

The present invention provides methods and compositions for identifying leukemic stem cells.

The present invention provides methods and compositions for identifying leukemic stem cells.

Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.

IgG epitope and applications thereof as a target are provided. The IgG epitope is the C.sub.H1 domain of non-B cell-derived IgG, and there is N-glycosylated sialic acid modification at the Asn162 site of the domain. The realization of its antigen functions must depend on the sialylation of the site. The present invention further discloses the applications of the IgG epitope as a drug target in preparing drugs for diagnosis and/or treatment of epithelial tumors. In addition, our studies showed that this antigen depends on the sialylation of Asn162 site as a drug target, and the sialylation of this site must depend on sialyltransferase ST3GAL4, indicating that the enzyme can be used as a drug target for preparing tumor therapeutic drugs. Further, integrin ?4 is co-expressed and co-localized with IgG containing the epitope. IgG can be used as a marker for preparing drugs for the auxiliary detection of epithelial tumors.

The present invention provides methods and compositions for identifying leukemic stem cells.